Myeloma Patients Europe (MPE)

EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE

Click Here Explore the latest AL amyloidosis
report about quality of life
and treatment experiences

Report “Health-related quality of life, diagnosis and treatment experiences of AL amyloidosis patients”

SHARED DECISION MAKING IN MYELOMA

Click Here

Fill in this survey to help MPE understand your experience making decisions with healthcare professionals

Complete the survey

The perspectives of myeloma patients and health care professionals on Minimal Residual Disease (MRD) section

Click Here

Check out all the MRD resources!

Explore the new myeloma and AL amyloidosis patient's guides available for download!

Click here

Check out the MPE patient guide section!

Read MPE's report Access barriers to myeloma clinical trials in Central and Eastern Europe

What is AL amyloidosis?

Learn about the condition

Click Here

Click Here

Myeloma Access Atlas

Find out more!

The Myeloma Access Atlas is an online platform designed to provide myeloma and AL amyloidosis patient advocates with the information they need to work effectively on access issues. It provides country-specific and comparative information on European health systems, including data on system performance and on access to treatment and care. Through the Atlas Coaching Programme, MPE provides advocacy tools and one-to-one support designed to help patient organisations develop and implement effective strategies to address identified access issues. Visit the Myeloma Access Atlas here.

Myeloma is a rare, incurable disease of the bone marrow and accounts for approximately one per cent of cancers. In this animated video, we explain what myeloma is, how it is diagnosed, its symptoms and its treatments.

MPE Advocate Development Programme→

The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to better serve patients locally, nationally and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders, including clinicians and industry, and the basics of evidence-based advocacy. Read more information here.